Eli Lilly announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.
The patent cliff cometh
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.
The article An Unsurprising Pipeline Failure originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.